Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 6/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.41 |
| ▸ | AGER | Q15109 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6443129 | 0.98 | GLA (0.49) | GLACNR2NCF1SMN1; SMN2NPC1 | |
| SCHEMBL9593490 | 0.95 | GLA (0.46) | GLACNR2NCF1SMN1; SMN2NPC1 | |
| SCHEMBL15144440 | 0.94 | CA9 (0.50) | GLACNR2NCF1SMN1; SMN2NPC1 | |
| SCHEMBL9052348 | 0.88 | GLA (0.40) | GLACNR2NCF1SMN1; SMN2LMNA | |
| SCHEMBL8751226 | 0.87 | GLA (0.42) | GLACNR2NCF1SMN1; SMN2L3MBTL1 | |
| SCHEMBL5441671 | 0.87 | CNR2 (0.50) | GLACNR2NCF1SMN1; SMN2NPC1 | |
| SCHEMBL3539599 | 0.86 | MAPT (0.43) | GLACNR2LMNAHTTMAPT | |
| SCHEMBL3512796 | 0.86 | MAPT (0.43) | GLACNR2LMNAHTTMAPT | |
| SCHEMBL3685046 | 0.85 | HCRTR2 (0.44) | SMN1; SMN2LMNARAB9AL3MBTL1CA12 | |
| SCHEMBL3691836 | 0.85 | CNR2 (0.46) | CNR2NCF1SMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6187083-B1 | INK COMPOSITION COMPRISING SELECTED INK VEHICLE, AMIDE VISCOSITY MODIFIER, CONDUCTIVE SULFONATE SALT ALL HAVING MELTING POINTS WITHIN SPECIFIED RANGE, COLORANT, OPTIONAL ANTIOXIDANT AND ULTRAVIOLET ABSORBER | XEROX CORPORATION | 2001-02-13 | — | — | US | claimed |
| US-20250179000-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2025-06-05 | — | — | US | disclosed |
| EP-4452918-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240190821-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF | TRIANA BIOMEDICINES INC (US) | 2024-06-13 | — | — | US | disclosed |
| WO-2024090531-A1 | CATION-CURABLE COMPOSITION | 日産化学株式会社 | 2024-05-02 | — | — | WO | disclosed |
| CN-117832615-A | Functional additive, electrolyte and lithium-sulfur battery | 江西微电新能源有限公司 | 2024-04-05 | — | — | CN | disclosed |
| WO-2023122276-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20220081737-A1 | POND REACTOR FOR RECOVERY OF METALS | CYCAD GROUP, LLC | 2022-03-17 | — | — | US | disclosed |
| US-20210340025-A1 | Compositions and Methods for Purification of Metals from Steel Making Waste Streams | CYCAD GROUP, LLC | 2021-11-04 | — | — | US | disclosed |
| EP-3853177-A1 | COMPOSITIONS AND METHODS FOR PURIFICATION OF METALS FROM STEEL MAKING WASTE STREAMS | Lixivia, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-0617028-A1 | Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulfonyl piperazine | U C B, S.A. (BE) | 1994-09-28 | — | — | EP | disclosed |
| US-5322681-A | Chelating compounds | NYCOMED IMAGING AS (NO) | 1994-06-21 | — | — | US | disclosed |
| EP-0287465-B1 | CYCLIC LIGANDS CONTAINING NITROGEN, METAL COMPLEXES FORMED BY THESE LIGANDS, DIAGNOSTIC COMPOSITIONS CONTAINING THEM AND PROCESS FOR THEIR PREPARATION | GUERBET S.A. (FR) | 1993-01-27 | — | — | EP | disclosed |
| EP-0499501-A2 | New macrocyclic nitrogen ligands, method for their preparation, metal complexes, diagnostic and therapeutic compositions | GUERBET S.A. (FR) | 1992-08-19 | — | — | EP | disclosed |
| WO-1992012978-A1 | NOVEL NITROGENOUS MACROCYCLIC LIGANDS, THEIR PREPARATION METHOD, POLYMETALLIC COMPLEXES, AND A DIAGNOSTIC AND THERAPEUTICAL COMPOSITION | GUERBET S.A. (FR) | 1992-08-06 | — | — | WO | disclosed |
| US-5049667-A | Nitrogen-containing cyclic ligands | GUERBET S.A. (FR) | 1991-09-17 | — | — | US | disclosed |
| EP-0417671-A2 | 3,4,5,6-Tetrahydro-2H-1,7,4-Benzodioxazonines as cardiovascular agents | BERLEX LABORATORIES, INC. (US) | 1991-03-20 | — | — | EP | disclosed |
| US-4966967-A | 3,4,5,6-tetrahydro-2H-1,7,4-benzodioxazonines as cardiovascular agents | BERLEX LABORATORIES, INC. (US) | 1990-10-30 | — | — | US | disclosed |
| EP-0287465-A1 | Cyclic ligands containing nitrogen, metal complexes formed by these ligands, diagnostic compositions containing them and process for their preparation | GUERBET S.A. (FR) | 1988-10-19 | — | — | EP | disclosed |
| US-4001279-A | CARRY INSOLUBLE REAGENT SUBSTANCES INTO SOLUTION IN NON-HYDROXYLIC MEDIA; CROWN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179000-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | GRM3, GRM2, GRM1 | GLA 3953/4885CNR2 213/4885NCF1 3829/4885 |
| US-20240190821-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF | PACSIN2, TPX2, PRSS12 | GLA 2236/4885CNR2 2070/4885NCF1 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.